Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

The role of targeted therapy and biomarkers in breast cancer treatment.

Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS.

Clin Exp Metastasis. 2012 Oct;29(7):807-19. doi: 10.1007/s10585-012-9496-y. Epub 2012 Jun 13. Review.

PMID:
22692561
2.

Progression and treatment of HER2-positive breast cancer.

Davoli A, Hocevar BA, Brown TL.

Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. doi: 10.1007/s00280-009-1208-1. Epub 2009 Dec 20.

PMID:
20087739
3.

What is triple-negative breast cancer?

Irvin WJ Jr, Carey LA.

Eur J Cancer. 2008 Dec;44(18):2799-805. doi: 10.1016/j.ejca.2008.09.034. Epub 2008 Nov 12. Review.

PMID:
19008097
4.

Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.

Roukos DH.

J Clin Oncol. 2010 Jun 10;28(17):e279-80; author reply e282-3. doi: 10.1200/JCO.2009.27.7061. Epub 2010 Apr 20. No abstract available.

5.

Directed therapy of subtypes of triple-negative breast cancer.

Carey LA.

Oncologist. 2011;16 Suppl 1:71-8. doi: 10.1634/theoncologist.2011-S1-71.

6.

[Triple-negative breast carcinoma--rewiev of current literature].

Rubovszky G, Udvarhelyi N, Horváth Z, Láng I, Kásler M.

Magy Onkol. 2010 Dec;54(4):325-35. doi: 10.1556/MOnkol.54.2010.4.6. Review. Hungarian.

7.

Triple-negative breast cancer: present challenges and new perspectives.

Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, Santoro F, Wouters H, Russnes HG, Sørlie T, Tagliabue E, Børresen-Dale AL; FEMME Consortium.

Mol Oncol. 2010 Jun;4(3):209-29. doi: 10.1016/j.molonc.2010.04.006. Epub 2010 Apr 24. Review.

8.

Biological therapy of breast cancer: recent clinical applications.

Baar J.

Curr Opin Investig Drugs. 2007 Dec;8(12):987-95.

PMID:
18058569
9.

Triple-negative breast cancer: an unmet medical need.

Hudis CA, Gianni L.

Oncologist. 2011;16 Suppl 1:1-11. doi: 10.1634/theoncologist.2011-S1-01. Review.

10.

[Endocrinology of breast cancer as a heterogeneous disease: a decade after the millennium].

Bershteĭn LM.

Vopr Onkol. 2013;59(3):292-8. Review. Russian. No abstract available.

PMID:
23909028
11.

Targeting basal-like breast cancers.

Dey N, Smith BR, Leyland-Jones B.

Curr Drug Targets. 2012 Nov;13(12):1510-24. Review.

PMID:
22974394
12.

Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer.

Reuben JM, Lee BN, Li C, Gao H, Broglio KR, Valero V, Jackson SA, Ueno NT, Krishnamurthy S, Hortobagyi GN, Cristofanilli M.

Breast J. 2010 May-Jun;16(3):327-30. doi: 10.1111/j.1524-4741.2010.00910.x. Epub 2010 Apr 12. No abstract available.

PMID:
20408820
13.

Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.

Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. Review.

14.

Biomarkers for personalized oncology: recent advances and future challenges.

Kalia M.

Metabolism. 2015 Mar;64(3 Suppl 1):S16-21. doi: 10.1016/j.metabol.2014.10.027. Epub 2014 Oct 30. Review.

PMID:
25468140
15.

Pharmacotherapy of triple-negative breast cancer.

Arslan C, Dizdar O, Altundag K.

Expert Opin Pharmacother. 2009 Sep;10(13):2081-93. doi: 10.1517/14656560903117309. Review.

PMID:
19640211
16.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
17.

Metastatic triple-negative breast cancer.

Rakha EA, Chan S.

Clin Oncol (R Coll Radiol). 2011 Nov;23(9):587-600. doi: 10.1016/j.clon.2011.03.013. Epub 2011 Apr 23. Review.

PMID:
21524569
18.

'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis.

Liu N, Wang X, Sheng X.

Curr Opin Obstet Gynecol. 2011 Feb;23(1):19-23. doi: 10.1097/GCO.0b013e32834252f5. Review.

PMID:
21150601
19.

Is triple negative a prognostic factor in breast cancer?

Nishimura R, Arima N.

Breast Cancer. 2008;15(4):303-8. doi: 10.1007/s12282-008-0042-3. Epub 2008 Mar 29.

PMID:
18369692
20.

Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe.

Gao S, Barber B, Schabert V, Ferrufino C.

Curr Med Res Opin. 2012 Jul;28(7):1111-8. doi: 10.1185/03007995.2012.694364. Epub 2012 Jun 6.

PMID:
22587480
Items per page

Supplemental Content

Write to the Help Desk